Dengue seroprevalence study in Bali

PLOS ONE RESEARCH ARTICLE Dengue seroprevalence study in Bali Sri Masyeni ID1*, Rois Muqsith Fatawy ID2, A. A. A. L. Paramasatiari3, Ananda Maheraditya3, Ratna Kartika Dewi3, N. W. Winianti3, Agus Santosa3, Marta Setiabudy3, Nyoman Trisna Sumadewi4, Sianny Herawati4 1 Faculty of Medicine and Health Science, Department of Internal Medicine, University of Warmadewa, Bali, Indonesia, 2 Faculty of Medicine, Infectious Disease and Immunology Research Center, Indonesia Medical Education and Research Institute, Universitas Indonesia, Jakarta, Indonesia, 3 Faculty of Medicine and Health Science, University of Warmadewa, Bali, Indonesia, 4 Faculty of Medicine, University of Udayana, Bali, Indonesia * masyeniputu@yahoo.com a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Masyeni S, Fatawy RM, Paramasatiari AAAL, Maheraditya A, Dewi RK, Winianti NW, et al. (2023) Dengue seroprevalence study in Bali. PLoS ONE 18(7): e0271939. https://doi.org/10.1371/ journal.pone.0271939 Editor: Kovy Arteaga-Livias, Universidad Nacional Hermilio Valdizan Escuela Academico Profesional de Medicina Humana, PERU Abstract Introduction Dengue infection poses significant public health problems in tropical and subtropical regions worldwide. The clinical manifestations of dengue vary from asymptomatic to severe dengue manifestations. This serological survey highlighted the high incidence of asymptomatic cases. This study aimed to determine the prevalence of dengue in healthy and ill adults in Bali. Methods Cross-sectional seroprevalence surveys were performed between July 2020 and June 2021 among healthy and ill adults in Denpasar Bali. Blood samples were collected from 539 randomly selected urban sites in Denpasar. Immunoglobulin G antibodies against the dengue virus were detected in serum using a commercial enzyme-linked immunosorbent assay kit. Received: July 10, 2022 Accepted: June 30, 2023 Published: July 14, 2023 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0271939 Copyright: © 2023 Masyeni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files. Results Overall, the dengue seroprevalence rate among the 539 clinically healthy and ill adults was high (85.5%). The median age was 34.1 (18–86.1). Most of the participants in the study were younger than 40 years (61.2%). Men were the dominant sex (54.5%). The study found a significant association between dengue seropositivity among people aged > 40 years and healthy status (p = 0.005; odds ratio [OR] = 0.459 and p < 0.001; OR = 0.336, respectively). The study reported that as many as 60% of the subjects had a history of previously suspected dengue infection. This study reflected the proportion of asymptomatic dengue patients requiring better assessment with a serological test. Conclusion The current study highlighted that real cases of dengue infection may be higher than reported, with a high prevalence of dengue seropositivity and a relatively dominant proportion of asymptomatic cases. The study guides physicians to be aware of every dengue infection in tropical countries and prevent the spread of the disease. PLOS ONE | https://doi.org/10.1371/journal.pone.0271939 July 14, 2023 1/7 PLOS ONE Funding: This work was supported by Grant from Ministry of Research and Higher Education Technology Indonesia to SM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. Dengue seroprevalence in Bali Introduction Dengue is considered a forthcoming disease, with alarming epidemiological patterns for both human health and the global economy [1]. The prevalence of dengue virus (DENV) infection has been predicted to cause 390 million new cases each year and approximately 96 million dengue hemorrhagic fever cases leading to hospitalization each year [2]. Four serotypes of DENV (DENV-1, -2, -3, and -4) have spread rapidly within countries and across regions, causing epidemics and severe dengue disease, hyperendemicity of multiple DENV serotypes in tropical countries, and autochthonous transmission in Europe and the USA [3,4]. However, the incidence of dengue and other infections has been reported to decrease during the pandemic [5,6]. The burden of dengue disease in many dengue-endemic countries, including Indonesia, remains poorly understood because current passive surveillance systems capture only a trivial fraction of all dengue cases. Furthermore, it mostly depends on clinical diagnosis, which excludes milder and atypical disease presentations [2,7]. Dengue transmission in Indonesia, including in Bali, has become hyperendemic and a significant public health problem. Dengue fever has spread throughout Indonesia since the first case was reported in Surabaya in 1968 [8]. All four dengue serotypes have been reported in Indonesian regions, including Western Java, Surabaya, Bali, and Jambi [3,9–13]. The previous study in Bali 2017, DENV-3 was predominant serotype (48%), followed by DENV-1 (28%), DENV-2 (17%), and DENV-4 (4%) [12]. In 2018, the most prevalent serotype was shifted to DENV-2 (48.7%), followed by DENV-3 (36.1%), DENV-1 (9.2%) and DENV-4 (3.4%) [11]. Dengue infection in Bali has become a recurring and significant public health concern. This study aimed to assess the seroprevalence of dengue infection detected using indirect immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA). Materials and methods Cross-sectional seroprevalence surveys were performed between July 2020 and June 2021 among healthy adults and non-dengue patients in Denpasar, Bali. Inclusion criteria was adult subject (> 18 years old) and signed informed consent where the healthy group was defined as the absence of signs of infection and other clinical manifestations of any illness. Subject with any illness was patients admitted to the hospitals with any illnesses and signed the informed consent. Subject was excluded from the study if they have a history of immune deficiency disease such as HIV, or chronic steroid user. Sampling method of the study employed consecutive sampling method. Numbers of samples needed was determined using the sample size hypothesis test for different proportions, with the first proportion in dengue cases and the second proportion as healthy exposed. pffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi pffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi 2 n ¼ ðz1 a=2 2Pð1 PÞ þ z1 b vP1ð1 P1Þ þ P2ð1 P2ÞÞ ð1Þ 2 ðP1 P2 Þ Where Za (1-alpha) with alpha 0.01 = 2.576, Zb (1-beta) with beta 0.05 = 1.96, P1 as case proportion = 70% (the prevalence from previous study in 2018), P2 as non-case p p proportion = 50% (an assumption). n = 〖(2.576 (2x0.6x(1–0.6)) +1.96 (0.7(1–0.7)+0.5(1– 0.5))) 〗^2/〖(0.7–0.5)〗^2 = 242.43. This means that the total samples required was 242 sample, minimally. Blood samples were collected from 539 randomly selected urban sites in Denpasar. DENV IgG antibodies were detected in serum. Each participant obtained a blood sample of 3 mL of venous blood in clot activator tubes. The serum was separated by centrifugation at 1300 ×g for PLOS ONE | https://doi.org/10.1371/journal.pone.0271939 July 14, 2023 2/7 PLOS ONE Dengue seroprevalence in Bali 10 min, kept at +4˚C, and transported to the laboratory of Universitas Warmadewa on the days for further processing. DENV anti-IgG antibody detection in the collected sera was performed using a commercial ELISA (catalog number EI 266a-9601-1 G, Panbio, Luebeck, Germany) following the manufacturer’s instructions. The specificity and sensitivity of the kit were 0.988 (95% confidence interval [CI]: 0.979–0.993) and 0.892 (95% CI: 0.879–0.903), respectively. Briefly, serum samples diluted 1:101 were added to microplates, and optical densities were measured using a microplate reader. Antibody values of � 20 relative units/mL were considered seropositive. Ethical considerations The study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Udayana University, Bali, Indonesia (approval no. 485/UN.14.2/KEP/2020). All study participants were enrolled after obtaining their written informed consent. Statistical analysis Descriptive analysis was used to describe dengue seroprevalence using an indirect IgG ELISA. The chi-squared test was used to analyze the association between variables. Results This study found a high prevalence of dengue infection among the participants. The seroprevalence in most age groups was higher than 80% (Fig 1). Moreover, the 41-45-year-old-group and older were observed to have a higher positivity rate than the younger group. As a result, in the following analysis, we divided the group into two age groups (< 40 and � 40 years groups). The baseline characteristics of the participants are listed in Table 1. The oldest age of the subject was 86 years old. The results showed a high prevalence of seropositive dengue among participants (Table 1). The study found 85.5% of the subject was Dengue antibody detected, of which 336 (72.9%) was healthy subject (Table 2). Among febrile subjects, the diagnosis was suspected viral infection other than Dengue diagnosis. The most diagnosis of non-febrile was acute diarrhoea, acute gastritis, diabetes mellitus, as high as 22.2%, 20% and 17,8%, respectively. Fig 1. Dengue antibody seroprevalence by age groups. https://doi.org/10.1371/journal.pone.0271939.g001 PLOS ONE | https://doi.org/10.1371/journal.pone.0271939 July 14, 2023 3/7 PLOS ONE Dengue seroprevalence in Bali Table 1. Baseline characteristics of the participants (N = 539). Variables Frequency Percentage (%) Age Median (IQR) 34.1 (18–86.1) < 40 years 330 61.2 � 40 years 209 38.8 Male 294 54.5 Female 245 45.5 Negative 72 13.4 Equivocal 6 1.1 461 85.5 Healthy 373 69.2 Any illness 166 37.8 Sex Indirect IgG dengue Positive Participants’ status Diagnosis (N = 166) COVID-19 43 25.9 Febrile illness 33 19.9 Non-febrile illness 90 54.2 COVID-19, coronavirus disease; IgG, immunoglobulin G; IQR, interquartile range. https://doi.org/10.1371/journal.pone.0271939.t001 Discussion The burden of dengue infection is not well-documented in Indonesia, particularly in the adult population. This is the first study on dengue seroprevalence among adult populations in Bali, where dengue is endemic. The current study findings, in which dengue seropositivity was as high as 85.5%, revealed that people in tropical countries are at risk of dengue infection. Another seroprevalence study reported a lower rate of dengue infection in Indonesian children (69.4%) [14]. This difference may be associated with a lower probability of Aedes bite among children than among adults. Our results are in line with those of another study in Thailand Table 2. Association between the variables. Variable Indirect IgG ELISA Positive Odds ratio Confidence interval (95%) p Negative N % N % Age < 40 years 330 271 82.1 59 17.9 � 40 years 209 190 90.9 19 9.1 Male 294 252 85.7 42 14.3 Female 245 209 85.3 36 14.7 Healthy 373 336 90.1 37 9.9 Any illness 166 125 75.3 41 24.7 0.005 0.459 0.265–0.796 0.893 0.968 0.598–1.566 < 0.001 0.336 0.206–0.548 Sex Participants’ status IgG, immunoglobulin G; DENV, dengue virus; ELISA, enzyme-linked immunosorbent assay; DHF, dengue hemorrhagic fever. https://doi.org/10.1371/journal.pone.0271939.t002 PLOS ONE | https://doi.org/10.1371/journal.pone.0271939 July 14, 2023 4/7 PLOS ONE Dengue seroprevalence in Bali that reported a high seroprevalence rate (91.5%) in adults and children in urban and rural areas [15]. A study in Dhaka reported a seroprevalence as high as 80% [16]. Carabali et al. [17] reported that the seroprevalence of dengue infection was 61%, and only 3.3% of seropositive subjects had a history of dengue [17]. A relatively small proportion (31.3%) of dengue seropositivity was found in a study in India [18]. The term seropositive dengue consists of IgM or IgG or both IgG, and IgM was positive. It was not clear the seropositivity of dengue based on IgG dengue only such as this study. The discrepancy may be explained by the study in India was conducted in both rural and urban areas, but not in our study provided in the urban area only. The current study also found that participants aged > 40 years had a significantly higher proportion of dengue seropositivity than participants aged < 40 years (p = 0.005). This finding may be related to the higher risk of Aedes bites than those who are younger. This is consistent with another study in Thailand, which found that more than 98% of participants older than 25 years were dengue seropositive [19]. In this study, the healthy group had a higher seroprevalence than any other illness group (90.1% vs 75.3%), with statistical significance (p<0.001). This result was in line with current finding where seropositivity was higher as age advanced. Study showed that as the longer people settle in a dengue-endemic area, risk of exposure were increased coupled with the lifelong persistence of anti-DENV antibodies [20]. Immunodeficiency may affect the production of the antibody and this already been used as an exclusion criterion. However, the assessment of the immune deficiency subject was merely based on the interview without any objective data therefore the ill subject has lower dengue seropositive rate, compared to healthy subjects. Since the history of suspected dengue infection was previously reported in only 60% of the participants, we predicted that there would be an asymptomatic dengue infection among the participants, compared with the results of the indirect IgG dengue ELISA. The study results reflect the proportion of asymptomatic dengue cases that need to be assessed with a serological study. With this high seroprevalence (85.5%), the population has a higher chance of being infected multiple times with dengue. Multiple exposures to this virus increase the risk of severe disease [21,22]. An individual infected with a different dengue serotype for the second time may experience an antibody-dependent enhancement of infection, which means that antibodies from the previous infection serve to disseminate the viral infection and increase viremia [21]. Even though no focus reduction neutralization test (FRNT) was done to confirm ADE, previous study in Indonesia reported that there were rather vast number of children had enhancing antibodies as measured by modified semi-adherent human erythroleukemia K562 cells assay and conventional neutralization test [23]. Another study also shown that there was enhancing antibody arrangement in contrast to Indonesian strains of DENV-2 and DENV-3 [24]. Therefore, the possibility of having a high number of hospitalized patients with dengue infection should be of concern to the Bali Public Health Office. The limitation of the study was recall bias related to dengue infection history among the participants. Since we only used indirect IgG ELISA, we were unable to distinguish between primary and secondary infections. On the other hand, the IgG antibodies of the DENV remain on the body for more than 5 years after the infection, and the disease from years prior may have been detected in this study. Indeed, the cross-reactivity among flavivirus infections needs to be determined with the plaque reduction neutralization test study, which is not the case in this study. Conclusions The current study highlighted a high prevalence of dengue seropositive individuals which indicates that a large proportion of the population already infected with dengue may have primary PLOS ONE | https://doi.org/10.1371/journal.pone.0271939 July 14, 2023 5/7 PLOS ONE Dengue seroprevalence in Bali dengue infection. Given the ADE theory that secondary infections lead to more severe dengue infections, this finding is very useful for physicians in the tropics to be alert to the occurrence of severe dengue infection. Supporting information S1 Fig. STROBE flowchart. (TIF) Acknowledgments We would like to thank all participants, nurses, and the research team at the Faculty of Medicine and Health Sciences, Universitas Warmadewa, for supporting this study. Author Contributions Conceptualization: Sri Masyeni. Data curation: A. A. A. L. Paramasatiari, Ananda Maheraditya, Ratna Kartika Dewi. Formal analysis: N. W. Winianti, Agus Santosa, Nyoman Trisna Sumadewi. Funding acquisition: Sri Masyeni. Investigation: Marta Setiabudy, Sianny Herawati. Writing – original draft: Sri Masyeni, Rois Muqsith Fatawy. Writing – review & editing: Rois Muqsith Fatawy. References 1. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016; 2(1):16055. https://doi.org/10.1038/nrdp.2016.55 PMID: 27534439 2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013 Apr; 496(7446):504–7. https://doi.org/10.1038/nature12060 PMID: 23563266 3. Masyeni S, Yohan B, Sasmono RT. Concurrent infections of dengue virus serotypes in Bali, Indonesia. BMC Res Notes. 2019; 12(1):129. https://doi.org/10.1186/s13104-019-4164-9 PMID: 30871630 4. Guzman MG, Harris E. Dengue. Lancet. 2015 Jan; 385(9966):453–65. https://doi.org/10.1016/S01406736(14)60572-9 PMID: 25230594 5. Prasertbun R, Mori H, Mahittikorn A, Siri S, Naito T. Pneumonia, influenza, and dengue cases decreased after the COVID-19 pandemic in Thailand. Trop Med Health. 2022; 50(1):27. https://doi.org/ 10.1186/s41182-022-00419-2 PMID: 35337390 6. Surendran SN, Nagulan R, Sivabalakrishnan K, Arthiyan S, Tharsan A, Jayadas TTP, et al. Reduced dengue incidence during the COVID-19 movement restrictions in Sri Lanka from March 2020 to April 2021. BMC Public Health. 2022; 22(1):388. 7. Gubler DJ. Dengue, Urbanization and Globalization: The Unholy Trinity of the 21st Century. Trop Med Health. 2011; 39(4SUPPLEMENT):S3–11. 8. Hotta S, Miyasaki K, Takehara M, Matsumoto Y, Ishihama Y, Tokuchi M, et al. Clinical and laboratory examinations on a case of “hemorrhagic fever” found in Surabaja, Indonesia, in 1968. Kobe J Med Sci. 1970; 16(4):203–10. PMID: 5514583 9. Kosasih H, Alisjahbana B, Nurhayati de Mast Q, Rudiman IF, Widjaja S, et al. The Epidemiology, Virology and Clinical Findings of Dengue Virus Infections in a Cohort of Indonesian Adults in Western Java. PLoS Negl Trop Dis. 2016 Feb 12; 10(2):e0004390. https://doi.org/10.1371/journal.pntd.0004390 PMID: 26872216 10. Wardhani P, Aryati A, Yohan B, Trimarsanto H, Setianingsih TY, Puspitasari D, et al. Clinical and virological characteristics of dengue in Surabaya, Indonesia. PLoS One. 2017 Jun 2; 12(6):e0178443. https://doi.org/10.1371/journal.pone.0178443 PMID: 28575000 PLOS ONE | https://doi.org/10.1371/journal.pone.0271939 July 14, 2023 6/7 PLOS ONE Dengue seroprevalence in Bali 11. Masyeni S, Yohan B, Somia IKA, Myint KSA, Sasmono RT. Dengue infection in international travellers visiting Bali, Indonesia. J Travel Med [Internet]. 2018 Jan 1; 25(1):tay061. Available from: https://doi. org/10.1093/jtm/tay061 PMID: 30113689 12. Megawati D, Masyeni S, Yohan B, Lestarini A, Hayati RF, Meutiawati F, et al. Dengue in Bali: Clinical characteristics and genetic diversity of circulating dengue viruses. PLoS Negl Trop Dis. 2017; 11(5):1– 15. https://doi.org/10.1371/journal.pntd.0005483 PMID: 28531223 13. Haryanto S, Hayati RF, Yohan B, Sijabat L, Sihite IF, Fahri S, et al. The molecular and clinical features of dengue during outbreak in Jambi, Indonesia in 2015. Pathog Glob Health [Internet]. 2016 Apr 2; 110 (3):119–29. Available from: https://doi.org/10.1080/20477724.2016.1184864 PMID: 27215933 14. Prayitno A, Taurel AF, Nealon J, Satari HI, Karyanti MR, Sekartini R, et al. Dengue seroprevalence and force of primary infection in a representative population of urban dwelling Indonesian children. PLoS Negl Trop Dis. 2017 Jun 15; 11(6):e0005621. https://doi.org/10.1371/journal.pntd.0005621 PMID: 28617803 15. Doum D, Overgaard HJ, Mayxay M, Suttiprapa S, Saichua P, Ekalaksananan T, et al. Dengue Seroprevalence and Seroconversion in Urban and Rural Populations in Northeastern Thailand and Southern Laos. Vol. 17, International Journal of Environmental Research and Public Health. 2020. https://doi. org/10.3390/ijerph17239134 PMID: 33297445 16. Dhar-Chowdhury P, Paul KK, Haque CE, Hossain S, Lindsay LR, Dibernardo A, et al. Dengue seroprevalence, seroconversion and risk factors in Dhaka, Bangladesh. PLoS Negl Trop Dis. 2017 Mar 23; 11 (3):e0005475. https://doi.org/10.1371/journal.pntd.0005475 PMID: 28333935 17. Carabali M, Lim JK, Velez DC, Trujillo A, Egurrola J, Lee KS, et al. Dengue virus serological prevalence and seroconversion rates in children and adults in Medellin, Colombia: implications for vaccine introduction. Int J Infect Dis. 2017 May; 58:27–36. https://doi.org/10.1016/j.ijid.2017.02.016 PMID: 28284914 18. Ukey PM, Bondade SA, Paunipagar P v., Powar RM, Akulwar SL. Study of seroprevalence of dengue fever in central India. Indian Journal of Community Medicine. 2010; 35(4):517–9. https://doi.org/10. 4103/0970-0218.74366 PMID: 21278875 19. Limkittikul K, Chanthavanich P, Lee KS, Lee JS, Chatchen S, Lim SK, et al. Dengue virus seroprevalence study in Bangphae district, Ratchaburi, Thailand: A cohort study in 2012–2015. PLoS Negl Trop Dis. 2022 Jan 4; 16(1):e0010021. https://doi.org/10.1371/journal.pntd.0010021 PMID: 34982768 20. Dhanoa A, Hassan SS, Jahan NK, Reidpath DD, Quek KF, Ahmad MP, et al. Seroprevalence of dengue among healthy adults in a rural community in Southern Malaysia: A pilot study. Infect. Dis. Poverty. 2018; 7:50–62. 21. Halstead SB. Neutralization and Antibody-Dependent Enhancement of Dengue Viruses. Adv Virus Res. 2003; 60:421–67. https://doi.org/10.1016/s0065-3527(03)60011-4 PMID: 14689700 22. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017 Nov; 358(6365):929–32. https://doi. org/10.1126/science.aan6836 PMID: 29097492 23. Yamanaka A, Tabuchi Y, Mulyanto KC, Susilowati H, Hendrianto E, Soegijanto S, et al. Dengue virus infection-enhancing and neutralizing antibody balance in children of the Philippines and Indonesia. Microbes and Infection. 2012; 14(13):1152–9. https://doi.org/10.1016/j.micinf.2012.07.013 PMID: 22841680 24. Yamanaka A, Oddgun D, Chantawat N, Okabayashi T, Ramasoota P, Churrotin S, et al. Dengue virus infection-enhancing antibody activities against Indonesian strains in inhabitants of central Thailand. Microbes and Infection. 2016; 18(4):277–84. https://doi.org/10.1016/j.micinf.2015.11.002 PMID: 26645957 PLOS ONE | https://doi.org/10.1371/journal.pone.0271939 July 14, 2023 7/7